


Clean Copy of the Pending Claims

4. A compound having the general structure:




wherein R<sub>1</sub>, R<sub>7</sub> and R<sub>8</sub> are independently selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>.

5. The compound of claim 4 wherein R<sub>7</sub> and R<sub>8</sub> are H;  
R<sub>1</sub> is H or F; and  
R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>.

14. A pharmaceutical composition comprising a compound selected from the group consisting of




wherein R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>; and


a pharmaceutically acceptable carrier.

15. The composition of claim 14 wherein said compound has the general structure



wherein  $R_9$  is selected from the group consisting of H, halo, haloalkyl and hydroxy; and  
 $R_3$  is hydroxy or  $-OCONH_2$ .

16. The composition of claim 15 wherein  $R_9$  is halo.
17. The composition of claim 15 wherein  $R_9$  is H or F; and  
 $R_3$  is  $-OCONH_2$ .
18. The composition of claim 15 wherein  $R_9$  is H or F; and  
 $R_3$  is hydroxy.
19. A compound having the general structure:



wherein  $R_1$ ,  $R_7$ ,  $R_8$ ,  $R_9$  and  $R_{10}$  are independently selected from the group consisting of H, halo, alkyl, haloalkyl,  $-NR_5R_6$ , hydroxy, and alkoxy;

$R_2$  is F or Cl;

$R_3$  is hydroxy or  $-OCONH_2$ ; and

$R_5$  and  $R_6$  are independently  $C_1$ - $C_4$  alkyl.

20. The compound of claim 19 wherein  
 $R_1$  and  $R_7$  are independently selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;  
 $R_2$  is F;  
 $R_3$  is hydroxy or  $-OCONH_2$ ; and  
 $R_8$ ,  $R_9$  and  $R_{10}$  are H.

21. The compound of claim 19 wherein  
R<sub>1</sub> and R<sub>8</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;  
R<sub>2</sub> is F;  
R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>; and  
R<sub>7</sub>, R<sub>9</sub> and R<sub>10</sub> are H.
22. The compound of claim 19 wherein  
R<sub>1</sub> is selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;  
R<sub>2</sub> is F;  
R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>; and  
R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub> and R<sub>10</sub> are H.
23. The compound of claim 22 wherein  
R<sub>1</sub> is selected from the group consisting of H, F, Cl, CF<sub>3</sub> and hydroxy.
24. The compound of claim 23 wherein  
R<sub>1</sub> is F.
25. A pharmaceutical composition comprising the compound of claim 19 and a pharmaceutically acceptable carrier.
26. A pharmaceutical composition comprising the compound of claim 22 and a pharmaceutically acceptable carrier.